Jessica Wade

San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Cooley advised the issuer for Mirum Pharmaceuticals’ $92 million follow-on offering of 4,000,000 shares of common stock at a public offering price of $23 per share. Mirum is a biopharmaceutical company developing and commercializing therapies for rare and debilitating liver diseases. Partner Jason Kent led the Cooley team.

Cooley advised Travere Therapeutics on its $316 million offering of 2.25% convertible senior notes due 2029. Travere Therapeutics is a biopharmaceutical company developing and commercializing therapies for people living with rare diseases. Partners Jason Kent, Mischi a Marca and Jason Savich led the Cooley team.

Cooley advised the initial purchasers on Global Blood Therapeutics’ Rule 144A offering of $345 million aggregate principal amount of 1.875% Convertible Senior Notes due 2028.  In connection with the offering, GBT entered into capped call transactions. Goldman Sachs & Co. and Jefferies acted as joint book-running managers for the offering. Global Blood Therapeutics is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Partners Kristin VanderPas, Charlie Kim, Dave Peinsipp, Mischi a Marca and Jason Savich led the Cooley team.

Cooley advised Vuori on its $400 million investment from SoftBank Vision Fund 2 at a valuation of $4 billion, marking one of the largest investments in a private apparel company. Vuori merges technical clothing with a West Coast aesthetic that looks and feels great. As Vuori embarks upon its next phase of growth,  it will continue to expand its product offerings, make key investments in infrastructure and people, and expand boost its sustainability efforts.